Vcanbio Cell & Gene Engineering Corp., Ltd.SSE: 600645

Report for Q3 2025

Oct 30, 2025 · Issued by Vcanbio Cell & Gene Engineering Corp., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 30, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-189

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Vcanbio Cell & Gene Engineering Corp., Ltd. on 6ix

Earlier from Vcanbio Cell & Gene Engineering

Announcement on the Return of Idle Raised Funds for Cash Management to the Dedicated Fundraising AccountSep 26, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Report Performance BriefingSep 5, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025Aug 28, 2025
Announcement on Wholly-owned Subsidiary Obtaining Notice of Acceptance for Application of Drug Clinical TrialsAug 5, 2025
Announcement on Resolutions of the 20th Extraordinary Meeting of the 11th Board of DirectorsJul 30, 2025

Later from Vcanbio Cell & Gene Engineering

Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical TrialsOct 31, 2025
Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025Nov 11, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025Nov 15, 2025
Announcement on Canceling the Board of Supervisors and Amending the "Articles of Association"Nov 28, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025Dec 11, 2025

All Vcanbio Cell & Gene Engineering news releases

Follow Vcanbio Cell & Gene Engineering into a list and get an email when it puts out news.

Follow Vcanbio Cell & Gene Engineering